Bayer
NICE wants more information on Xarelto
March 13, 2012Sales and Marketing Bayer, DVT, NICE, Xarelto
NICE is asking Bayer for more information about its blood thinner Xarelto in new guidance. The watchdog is currently minded …
Former Bayer man becomes senior VP of Sanofi’s Asia region
March 5, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Asia, Bayer, Sanofi
Sanofi has appointed Jean-Luc Lowinski as its new senior vice president of the Asia region, effective from 1 May. Jean-Luc …
Werner Wenning proposed as chairman of the supervisory board at Bayer
February 24, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Schneider, Wenning
Former Bayer chief executive Werner Wenning is set to be elected to the supervisory board at Bayer with effect from October. …
Bayer eye drug succeeds in long-term study
February 21, 2012Research and Development, Sales and Marketing Bayer, Lucentis, aflibercept, wet AMD
Bayer’s eye drug aflibercept has succeeded in a long-term study in patients with a common eye condition. The Phase III …
Bayer UK/Ireland appoints new chief financial officer
February 9, 2012Business Services, Sales and Marketing Bayer, Ute Bockstegers
Bayer has appointed Ms Ute Bockstegers as chief financial officer and head of business administration and partnering.Ute Bockstegers comes to …
Bayer’s colorectal cancer drug increases survival
January 19, 2012Research and Development, Sales and Marketing Bayer, colectoral cancer, regorafenib
Bayer and Onyx’s colorectal cancer drug regorafenib increased overall survival for late-stage patients, according to new data. The Phase III …
Lucentis rival gains US approval
November 22, 2011Research and Development, Sales and Marketing Bayer, Eylea, Lucentis, Novartis, Regeneron, Roche
A rival to Roche and Novartis’ drug Lucentis has received FDA approval for a common form of eye disease. Eylea …
Bayer forecasts €11 billion growth in Asia
November 17, 2011Bayer, China, emerging markets
Bayer is expecting sales in Asia to grow by €11 billion over the next four years, with over half of …
Xarelto succeeds in new study
November 14, 2011Sales and Marketing Bayer, FDA, J&J, JJ, Xarelto
In a new study J&J and Bayer’s blood thinner Xarelto reduced deaths in patients after a heart attack, which could …
Emerging markets help Bayer through tough quarter
October 28, 2011Sales and Marketing Bayer, Xarelto, emerging markets
Bayer has posted modest results for the third quarter, with growth in emerging markets compensating for austerity measures in Europe …
Abbott spin-off could attract mega merger
October 21, 2011Research and Development, Sales and Marketing Abbott, Bayer, Humira, Merck, Roche
Abbott’s new spin-off pharma firm could attract a lot of attention from big pharma looking to sure up their portfolios. …
Bayer planning joint venture to make drugs in Russia
October 12, 2011Manufacturing and Production Bayer, pharma manufacturing news
Germany’s Bayer AG has joined a number of its peers in the pharmaceutical industry with the signing of an agreement …
Digital Pharma: Twitter slip-up shouldn’t silence pharma
September 9, 2011Medical Communications, Sales and Marketing Bayer, Code of Practice, Digital Pharma blog, PMCPA, Twitter
Bayer UK was recently ruled to have breached the ABPI Code of Practice by promoting prescription-only medicines to the general …
FDA fast tracks Bayer prostate cancer drug
August 23, 2011Sales and Marketing Algeta, Alpharadin, Bayer, prostate cancer
Bayer’s potential blockbuster prostate cancer drug Alpharadin has been granted a fast track review by the FDA, meaning it could …
Digital Pharma: Bayer reprimanded over social media use
August 17, 2011Medical Communications ABPI Code of Practice, Bayer, Digital Pharma blog, PMCPA
Bayer will be named in the medical press after being found guilty of the first social media breach of the …
Latest content
